Nasdaq News

We're now a summer removed from the day that Blue Apron Holdings (NYSE: APRN) and Beyond Meat (NASDAQ: BYND) became partners. The provider of gourmet meal kits teamed up with the fast-growing provider of plant-based foods to offer Beyond Burger patties to enhance its existing v

As COVID-19, the illness caused by the novel coronavirus, spread throughout the world, researchers have been testing both old and new treatments in attempts to find a cure. One that has drawn particular attention is hydroxychloroquine, a common malaria drug.

One of the lessons that became clear during the recent bear market is that not all stocks are created equal. The widespread concern about the COVID-19 pandemic gave rise to the fastest bear market slump in stock market history. The market peaked on Feb. 18, and the S&P 500 

If you've ever donated to a nonprofit, you know how rewarding it is to contribute to a worthy cause. Nonprofit health organizations bridge the gap between public and private resources by disseminating information, contributing directly to key efforts or individuals, and advocati

When the internet becomes infatuated with a stock, that's a red flag for long-term investors, but it's not always a sign that you should stay away. Genius Brands (NASDAQ: GNUS) has been the subject of much online speculation as day traders have bid up the stock of the company th

For years, experts have warned that Social Security is in serious financial trouble. In fact, the most recent projections from the Social Security trustees indicated the program's trust fund will run short in 2035, requiring a major cut to benefits. And the coronavirus isn't hel

Let's face it: Some companies that are receiving a lot of hype right now about their COVID-19 programs won't have staying power. Small biotechs claiming to have a game-changing treatment on the way could run into the harsh realities of clinical testing. Diagnostic test makers wi

It's easy for investors in Ford (NYSE: F) and General Motors (NYSE: GM), or other automakers, to brush off Hertz's (NYSE: HTZ) recent bankruptcy thinking it has no effect on the manufacturers. But that thinking could be wildly incorrect, and in fact Hertz's bankruptcy could actu

Genetic and diagnostic testing start-ups are at the forefront of providing health information as a service for consumers. As is frequently the case in emerging markets, no two testing start-ups have the same value proposition or strategic vision for growth.

Warren Buffett isn't winning so far in 2020. Shares of his beloved Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) are underperforming the S&P 500 index by around 15%. Most of the individual stocks owned by Berkshire remain in negative territory year to date.

There's a growing movement for marijuana legalization in the U.S. and around the world. And a key part in winning regulators over is in showing them that the industry can be trusted to govern itself. However, the problem for the industry is that there's too much excitement surro

There's little question that when 2020 comes to a close, investors will not soon forget it.

FXEmpire.com - The Stats It was a relatively busy week on the economic calendar, in the week ending 19th June.

Related: Drug Dealer Just Sentenced to 25 Years Hoped to Build a Better Bitcoin Miner

“His management experience and expertise in financial regulation give him an ideal background to lead the United States Attorney’s Office for the Southern District of New York, and he will be a worthy successor to the many historic figures who have held that post.”

Related Stories

• Three Arrows Capital Now Holds More Than 6% of Grayscale’s $3.6B Bitcoin Trust
• SEC Moves to Freeze Assets of Alleged $12M Crypto Investment Scam

Investors in Zogenix, Inc. ZGNX need to pay close attention to the stock based on moves in the options market lately. That is because the July 17, 2020 $35.00 Call had some of the highest implied volatility of all equity options today.What is Implied Volatility?Implied volatilit

LiveXLive Media, Inc. LIVX was a big mover last session, as the company saw its shares rise more than 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now t

For years now, Aurora Cannabis (ACB) and Canopy Growth (CGC) have traded in near lockstep based on the global growth potential of cannabis. The latest quarterly results set Aurora Cannabis a step ahead of their prime competitor in Canada.

Aurora Cannabis reported an exceptional turnaround quarter for March, but the stock has taken a hit following the weak Canopy Growth results at the end of May. Oddly, Aurora Cannabis now appears better positioned to thrive having already had to tighten their financial purse strings due to cash concerns.

Value Brand Shift

Canopy Growth called out a prime reason for their failure to hit revenue targets in the March quarter due to the market shift to value brands. Aurora Cannabis made this move to shift production towards the value brand Daily Special in early Q1.

For this reason, Aurora Cannabis saw recreational cannabis sales grow sequentially by C$8 million to C$42 million. Canopy Growth saw recreational cannabis slip by C$20 million to C$49 million. Canopy Growth was too busy focused on the struggling cannabis beverages startup and missed the recreational cannabis shift to more affordable products to compete against illegal weed.

Aurora Cannabis has already shown an ability to shift quicker than Canopy Growth. The latter is still going through a complete leadership change with executives from the liquor sector possibly not as familiar with cannabis.   

Focus, Focus, Focus

One of my biggest complaints about the Canadian cannabis LPs was the focus on global operations. The companies were going after massive markets in Canada, the U.S. and in Europe, Latin America, Australia and even Africa. The vast operations made little sense for companies trying to build new markets. Building market share in recreational cannabis in Canada and CBD in the U.S. was more than complicated enough for executive leaders to not need further operations in Germany, Columbia or Australia.

Aurora Cannabis made the decision in February to reduce operating costs by over 50% to below C$45 million per quarter. The company shifted out of most international locations with a focused shifted to Canada, U.S. and Germany.

The Canadian company has a singular focus on profitable growth now while Canopy Growth still appears to be investing in money losing businesses for a payoff in out years. Aurora Cannabis now has the upper hand here with a path to EBITDA profits in the September quarter while Canopy Growth pulled guidance for the rest of the year while generating substantial EBITDA losses in the March quarter.

C$27 Price Target

What would you tell someone if they were to ask you, “Should I buy Aurora Cannabis stock right now?” For Cantor analyst Pablo Zuanic the answer is quite clear — the analyst sees the stock as a plant that keeps blossoming.

"ACB is a company with a credible turnaround plan, not going bust, and with little further dilution risk. ACB is a close #2 in Canada rec to Canopy Growth; it is #1 in Canada med with share north of 40%; and it has reconfigured its international business, but its opportunities are not less than those of peers," Zuanic noted.

Wieser rates ACB a Buy along with a C$27 price target, which implies nearly 50% upside from current levels.

Takeaway

The key investor takeaway is that the valuation equation for Aurora Cannabis is far more compelling here as the market has pushed the stock back down below $14. The stock has a far better valuation at $1.5 billion with FY21 sales estimates near $300 million while Canopy Growth trades at $6.3 billion with sales estimates near $400 million.

Aurora Cannabis is a far better deal, if an investor can purchase the stock closer to my $10 target. Regardless, the company has leap frogged Canopy Growth as the better investment due to their improved financials.

To find good ideas for cannabis stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

Disclosure: No position.

The coronavirus-racked global economy hasn't affected the move toward modern payment methods. At least that's what new research from finance-sector titan Mastercard (NYSE: MA) seems to indicate.

Concerns that the resumed Australian A-League soccer competition would not be televised ended late on Friday with Football Federation Australia (FFA) reaching a broadcast deal stretching until next July with a realignment of the 2021 season.

What happened HEXO (NYSE: HEXO) and Organigram Holdings (NASDAQ: OGI) both declined more steeply than the overall stock market on Friday (in excess of 3% in both cases).